WT1 and neoplasm: Looking toward adoptive T cell therapy, a WT1 [126–134]/A2-specific TCR isolated from peptide-specific, allo-induced CTLs (107, 142), exhibited good anti-tumor responses in a mouse xenograft model with TCR-transduced T cells (143, 144).